Parkinson vaccination: Proof of Concept for AFFiRiS AG
AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept"). The company is now starting to prepare for clinical trials of the vaccine which are planned to commence at the beginning of 2011. Due to a completely innovative effect approach this vaccine could for the first time offer a chance of treating the causes of Parkinson's disease. The basis of PD01 is the company's AFFITOM® technology, on which two vaccines for Alzheimer's disease are based that have already successfully completed their initial clinical studies. The Parkinson's vaccine specifically acts against a protein known as alpha-synuclein (alpha-syn) which strongly contributes to the clinical profile of Parkinson's disease.
Referring to the successful completion of the preclinical development phase, Dr Walter Schmidt, director and co-founder of AFFiRiS AG stated: "We have had PD01 evaluated in various preclinical systems. All the tests have shown that this vaccine works against alpha-syn. In addition to histological and biochemical analyses, we have even been able to observe behavioural improvements as a result of our vaccination. We are now starting preparations for the clinical trial of PD01 which will supplement our current clinical programmes".
The vaccine PD01 takes advantage of the fact that accumulations and the associated deposition of alpha-syn in the brain are partly responsible for the progression of Parkinson's disease. A reduction in the alpha-syn concentration in the brain should therefore have a positive effect on the clinical progression of Parkinson's. It is precisely here where PD 01 acts, as the vaccine triggers an effective immune response to the harmful alpha-syn, as a result of which the body's own immune system reduces the alpha-syn. AFFiRiS is now able to announce the successful outcome of the preclinical phase confirming the effectiveness of this principle.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.